Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents.

PubWeight™: 0.88‹?›

🔗 View Article (PMC 3176173)

Published in Onco Targets Ther on August 09, 2011

Authors

Mohammad K Khan1, Niloufer Khan, Alex Almasan, Roger Macklis

Author Affiliations

1: Taussig Cancer Institute, Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA.

Articles cited by this

Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Melanoma. N Engl J Med (2006) 8.80

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol (2005) 8.33

Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76

Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol (2003) 3.13

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg (1998) 3.11

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer (2006) 2.44

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol (2001) 2.41

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40

Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A (1995) 2.27

Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06

Toward a molecular classification of melanoma. J Clin Oncol (2007) 1.95

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 1.93

Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer (2003) 1.80

Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin (2000) 1.79

Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest (2010) 1.74

Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52

Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol (1996) 1.48

A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest (2004) 1.46

Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene (2010) 1.36

The radiation response of human malignant melanoma cells grown in vitro. Cancer Res (1971) 1.36

Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer (2005) 1.35

The controversial abscopal effect. Cancer Treat Rev (2005) 1.34

Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther (2004) 1.33

Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol (2009) 1.32

Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest (2010) 1.28

The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg (2003) 1.28

Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ (2000) 1.25

Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys (2004) 1.25

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer (2010) 1.24

Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22

Radiation biology of malignant melanoma. Acta Radiol Oncol (1986) 1.17

A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets (2004) 1.16

Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys (1991) 1.15

Melanocytes in development and cancer. J Cell Physiol (2010) 1.15

Decreased energy metabolism extends life span in Caenorhabditis elegans without reducing oxidative damage. Genetics (2010) 1.13

Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol (2009) 1.11

Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys (2002) 1.07

Clinical radiobiology of malignant melanoma. Radiother Oncol (1989) 1.07

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer (2009) 1.02

Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer (2004) 1.01

p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell (2008) 1.01

Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol (2006) 1.01

Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01

Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis (2008) 0.99

Radioprotection: smart games with death. J Clin Invest (2010) 0.98

A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol (2006) 0.96

Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys (2006) 0.96

Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol (1986) 0.95

Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology (1987) 0.90

Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys (2005) 0.90

Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park) (2004) 0.88

A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys (1985) 0.88

An update on adjuvant interferon for melanoma. Cancer Control (2002) 0.87

Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res (2011) 0.87

Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study. Melanoma Res (2004) 0.87

Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res (2007) 0.86

Novel therapeutics for the treatment of metastatic melanoma. Future Oncol (2009) 0.86

Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett (1997) 0.85

Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg (1990) 0.84

Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol (2008) 0.83

Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys (2002) 0.83

Malignant melanoma: the role of radiation therapy revisited. Semin Oncol (1996) 0.82

Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity. Radiother Oncol (2008) 0.80

Radiation therapy of primary and metastatic melanoma. Ann N Y Acad Sci (1963) 0.80

Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection. Melanoma Res (2003) 0.80

Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases. Anticancer Res (2009) 0.80

Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth. Mol Med Rep (2011) 0.78

Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol (2010) 0.77

Interferon-alpha combined with radiotherapy in the treatment of unresectable melanoma. Cancer Invest (2001) 0.76

Taking the guesswork out of uveal melanoma. N Engl J Med (2010) 0.76

Articles by these authors

Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol (2005) 2.28

Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene (2004) 1.57

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer (2007) 1.41

Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg (2010) 1.28

Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene (2002) 1.18

Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res (2003) 1.16

Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms' tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms' Tumor Study Group. Int J Radiat Oncol Biol Phys (2003) 1.14

Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab (2012) 1.12

Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer (2008) 1.11

Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys (2012) 1.06

Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer (2007) 1.05

The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys (2011) 1.04

Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem (2003) 1.04

Retracted Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol (2005) 1.00

Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta. J Interferon Cytokine Res (2007) 0.95

Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer (2009) 0.92

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma (2011) 0.90

Retracted Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J Virol (2005) 0.86

Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidylcholine. Evidence for FGF-2 release from cells not extracellular matrix. Vascul Pharmacol (2002) 0.84

The impact of functional imaging on radiation medicine. Radiat Oncol (2008) 0.84

Plaque brachytherapy for uveal melanoma: a vision prognostication model. Int J Radiat Oncol Biol Phys (2012) 0.82

External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma. Int J Radiat Oncol Biol Phys (2010) 0.82

HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis (2011) 0.82

Redox Regulation of Apoptosis before and after Cytochrome C Release. Korean J Biol Sci (2003) 0.82

p53 binding to target sites is dynamically regulated before and after ionizing radiation-mediated DNA damage. J Environ Pathol Toxicol Oncol (2004) 0.81

Sustained apoptosis in human cardiac allografts despite histologic resolution of rejection. Transplantation (2003) 0.79

Bilateral panocular involvement with mantle-cell lymphoma. J Clin Oncol (2008) 0.79

Radiation therapy: orbital tumors. Dev Ophthalmol (2013) 0.78

In regards to Hall: intensity-modulated radiation therapy, protons, and the risk of second cancers (Int J Radiat Oncol Biol Phys 2006;65:1-7). Int J Radiat Oncol Biol Phys (2006) 0.78

Low-grade follicular lymphoma of the small intestine: a challenge for management. Semin Oncol (2011) 0.75

Teletherapy: advanced techniques. Dev Ophthalmol (2013) 0.75

Dosimetric benefit of a new ophthalmic radiation plaque. Int J Radiat Oncol Biol Phys (2012) 0.75

Multiple unit umbilical cord blood transplantation with total body irradiation, etoposide and antithymocyte globulin for adult haematological malignancy patients. Br J Haematol (2010) 0.75

Brachytherapy. Dev Ophthalmol (2013) 0.75

Introduction to radiotherapy and standard teletherapy techniques. Dev Ophthalmol (2013) 0.75